Searchable abstracts of presentations at key conferences in endocrinology

ea0016s24.2 | State of the art in the therapy of pituitary disease | ECE2008

Medical therapy of Cushing’s disease

Pivonello Rosario

The first-line therapy of Cushing’s disease (CD) is pituitary surgery, whereas pituitary radiotherapy and bilateral adrenalectomy represent alternative treatments for patients not cured by surgery. Medical therapy has a minor role in the management of CD, and it is mainly based on the use of two different categories of drugs, the adrenal-blocking drugs, which act at the adrenal level, and the neuromodulatory drugs, which act at the pituitary level. These drugs are not usu...

ea0073ap4 | Clinical Endocrinology Trust Lecture | ECE2021

Advances on complications and therapy of cushing’s syndrome

Pivonello Rosario

In the last decade, new evidence on Cushing’s syndrome (CS) complications and therapies have gradually emerged. CS is associated with well known systemic complications, mainly including metabolic syndrome, cardiovascular disease, immune and infectious disorders, skeletal diseases, neuropsychiatric disorders, as well as impairment of gonadal function with impact on reproduction and sexuality. However, more recently several studies specifically focused on muscle and brain s...

ea0090ep801 | Pituitary and Neuroendocrinology | ECE2023

An Open-Label Extension Study to Evaluate the Safety of Long-term Use of Relacorilant in Patients With Endogenous Cushing Syndrome

Badiu Corin , Mariash Cary N. , Kautzky-Willer Alexandra , Shlomai Gadi , Aresta Carmen , Pivonello Rosario , Dischinger Ulrich , Bancos Irina , Dobri Georgiana , Hamrahian Amir , Auchus Richard , Feelders Richard , Recasens Monica , Chmiel-Perzynska Iwona , Pearson Emily , Moraitis Andreas G. , Araque Katherine

Cushing syndrome (CS) is a chronic and debilitating condition with high morbidity and mortality. Development of novel, safe, and effective pharmacologic therapies with improved risk-benefit profiles would enrich treatment options for patients. Relacorilant is a selective glucocorticoid receptor (GR) modulator that competitively antagonizes cortisol activity and, unlike the FDA-approved GR antagonist mifepristone, does not bind to the progesterone receptor. In a phase 2 study i...

ea0063oc3.1 | Cushing's and acromegaly | ECE2019

Osilodrostat provides clinical benefit over 48 weeks in patients with Cushing disease: Results from the LINC 3 study

Pivonello Rosario , Fleseriu Maria , Newell-Price John , Bertagna Xavier , Findling James , Shimatsu Akira , Gu Feng , Auchus Richard , Leelawattana Rattana , Jig Lee Eun , Hee Kim Jung , Lacroix Andre , Laplanche Audrey , O'Connell Paul , M Pedroncelli Alberto , Tauchmanova Libuse , MK Biller Beverly

Introduction: Osilodrosat is a potent oral 11β-hydroxylase inhibitor. During the 24-week, single-arm, open-label period of the Phase III LINC 3 study (NCT02180217), osilodrostat treatment demonstrated rapid, sustained reduction in mean urinary free cortisol (mUFC) in most Cushing disease (CD) patients. In the subsequent 8-week, double-blind, randomized-withdrawal phase, a significantly higher proportion of patients receiving osilodrostat maintained normal mUFC at week (W)...

ea0029p202 | Calcium & Vitamin D metabolism | ICEECE2012

Vitamin D pathway in non-functioning pituitary adenomas

Vuolo L. , Di Somma C. , Negri A. , Pivonello C. , Savanelli M. , Faggiano A. , Guerra E. , Pivonello R. , Colao A.

Introduction: In addition to its well known effects on calcium homeostasis and bone metabolism, growing evidences shows that vitamin D plays an important role in regulation of cancer angiogenesis, cell apoptosis, differentiation, and proliferation. Vitamin D acts through vitamin D receptor (VDR), an intracellular nuclear receptor. It was found an association between different cancer histotypes and single nucleotide polymorphisms (SNPs) of VDR. Despite the close relationship be...

ea0029p781 | Endocrine tumours and neoplasia | ICEECE2012

Hepatocellular carcinoma (HCC) as a neuroendocrine tumor: a preliminar molecular study.

Pivonello C. , Vitale G. , Izzo F. , Di Sarno A. , Giorgio A. , Hofland L. , Colao A. , Pivonello R.

Hepatocellular carcinoma (HCC) is often diagnosed at late stage or metastatic condition. Surgical resection is considered treatment of choice and other treatment options include chemoembolization, radiofrequency ablation and photodynamic therapy. We evaluated the expression levels of the 5 somatostatin receptors (SSTRs) in 23 biopsies of HCC patients and also mTOR, p70S6K and 4eBP1 in HuH-7 and HepG2 and investigated the in vitro effect of somatostatin analogs (SA) and ...

ea0026p75 | Endocrine tumours and neoplasia | ECE2011

T-type calcium channel blockers inhibit hormone secretion and induce apoptotic cell death in a medullary thyroid cancer cell line

Pivonello R , Pivonello C , Cavaccini A , Sarnataro M , Cariati F , Faggiano A , Colao A , Cataldi M

Medullary thyroid carcinoma (MTC) accounts for ~5–10% of thyroid cancers. Intense efforts are currently directed toward the identification of new druggable targets for the treatment of MTC. The aim of this study was to investigate whether drugs acting at voltage-gated T-type calcium channels could affect hormone release and/or cell proliferation in a MTC cell line, the TT cells. The expression of the three isoforms of T-type calcium channels (CaV3.1, CaV3.2 and CaV3.3) wa...

ea0081ep700 | Pituitary and Neuroendocrinology | ECE2022

A Delphi panel of Italian endocrinologists to define the unmet needs on the current management of Cushing’s Syndrome

Pivonello Rosario , Carla Scaroni , Polistena Barbara , Migliore Antonio , Giustina Andrea

Introduction: Cushing’s Syndrome (CS) requires an accurate diagnosis, patient-tailored treatments and long-term management. To define the unmet needs of patients with CS, a consensus among a panel of Italian endocrinologists was promoted. The panel involved 57 specialists with expertise in CS management.Methods: The endocrinologists were identified by convenience sampling. The survey was built around a set of statements formulated after literature r...

ea0029p836 | Endocrine tumours and neoplasia | ICEECE2012

Vitamin D from genetics to the clinical in prostate cancer

Cariati F. , Negri A. , Pivonello C. , Ferro M. , Sarnataro M. , Terracciano D. , Galdiero M. , Vitale P. , Altieri V. , Colao A. , Pivonello R.

Background: The prostate cancer (CaP) is among the most commonly diagnosed cancers, accounting for about 20% of all newly diagnosed cancers. Subject of recent studies is the role of vitamin D in the pathogenesis of CaP. Literature data speculated about the role of vitamin D in the progression of Cap. In addition, several studies have shown an association between VDR gene polymorphism FokI and CaP especially in the Asian population.Objective: The aim of t...

ea0022p49 | Adrenal | ECE2010

In vitro effect of dopastatins on hormone secretion in adrenal tumors

Pivonello Claudia , Napolitano Tiziana , De Leo Monica , Cozzolino Alessia , Vitale Pasquale , Lombardi Gaetano , Colao Annamaria , Pivonello Rosario

Somatostatin (SSTRs) and dopamine (DRs) receptors are expressed in adrenal tumors. It has been demonstrated in pituitary and neuroendocrine tumors that somatostatin-dopamine chimeric molecules, namely dopastatins, which bind both somatostatin (SST2 and/or SST5) and dopamine (D2) receptors, exert a more potent action compared with the single receptor agonists in experimental settings. The aims of this study were to evaluate the expression of DRs and SSTRs, and the effects of do...